HIGHLIGHTS
- What: The authors aim to discuss resistance to fgSRLs identify second-line therapy determinants and assess glycemia`s impact to provide valuable insights for acromegaly management in clinical practice.
- Who: S. Grottoli from the Department of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy have published the research work: Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management, in the Journal: (JOURNAL)
- How: PASI is not recommended in uncontrolled T2DM patients because of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.